冠心病的精准治疗

摘要/Abstract

中图分类号:

R541.4

陈航炜, 戴秋艳. 冠心病的精准治疗[J]. 内科理论与实践, 2021, 16(03): 212-216.

参考文献41

[1]	Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis[J]. Circ Res, 2016, 118(4): 620-636. doi:10.1161/CIRCRESAHA.115.306301pmid:26892962
[2]	Malakar AK, Choudhury D, Halder B, et al. A review on coronary artery disease, its risk factors, and therapeutics[J]. J Cell Physiol, 2019, 234(10): 16812-16823. doi:10.1002/jcp.28350pmid:30790284
[3]	Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update[J]. Circulation, 2020, 141(9): e139-e596.
[4]	Zhao D, Liu J, Wang M, et al. Epidemiology of cardiovascular disease in China: current features and implications[J]. Nat Rev Cardiol, 2019, 16(4): 203-212. doi:10.1038/s41569-018-0119-4 URL
[5]	Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease[J]. Circulation, 2019, 140(11): e596-e646. doi:10.1161/CIR.0000000000000678
[6]	Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J, 2020, 41(3): 407-477. doi:10.1093/eurheartj/ehz425 URL
[7]	Yusuf S, Joseph P, Dans A, et al. Polypill with or without aspirin in persons without cardiovascular disease[J]. N Engl J Med, 2021, 384(3): 216-228. doi:10.1056/NEJMoa2028220 URL
[8]	Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease[J]. J Am Coll Cardiol, 2016, 68(10): 1082-1115. doi:10.1016/j.jacc.2016.03.513pmid:27036918
[9]	Kvasnicka T, Malikova I, Zenahlikova Z, et al. Rivaroxaban - metabolism, pharmacologic properties and drug interactions[J]. Curr Drug Metab, 2017, 18(7): 636-642. doi:10.2174/1389200218666170518165443pmid:28524005
[10]	Gurbel PA, Fox KAA, Tantry US, et al. Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease[J]. Circulation, 2019, 139(18): 2170-2185. doi:10.1161/CIRCULATIONAHA.118.033580pmid:31034291
[11]	Thomas CD, Johnson JA. Pharmacogenetic factors affecting β-blocker metabolism and response[J]. Expert Opin Drug Metab Toxicol, 2020, 16(10): 953-964. doi:10.1080/17425255.2020.1803279 URL
[12]	Lee JS, Chang PY, Zhang Y, et al. Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status[J]. Diabetes Care, 2017, 40(4): 529-537. doi:10.2337/dc16-1958 URL
[13]	中华医学会心血管病学分会, 中国康复医学会心脏预防与康复专业委员会, 中国老年学和老年医学会心脏专业委员会, 等. 中国心血管病一级预防指南[J]. 中华心血管病杂志, 2020, 48(12): 1000-1038.
[14]	Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias[J]. Eur Heart J, 2020, 41(1): 111-188. doi:10.1093/eurheartj/ehz455 URL
[15]	Lee SE, Chang HJ, Sung JM, et al. Effects of statins on coronary atherosclerotic plaques[J]. JACC Cardiovasc Imaging, 2018, 11(10): 1475-1484. doi:10.1016/j.jcmg.2018.04.015 URL
[16]	Agrawal H, Choy HK, Liu J, et al. Coronary artery disease[J]. Arterioscler Thromb Vasc Biol, 2020, 40(7): e185-e192.
[17]	Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy[J]. Lancet, 2016, 388(10059): 2532-2561. doi:S0140-6736(16)31357-5pmid:27616593
[18]	Qamar A, Giugliano RP, Bohula EA, et al. Biomarkers and clinical cardiovascular outcomes with ezetimibe in the IMPROVE-IT trial[J]. Am Coll Cardiol, 2019, 74(8): 1057-1068. doi:10.1016/j.jacc.2019.06.038 URL
[19]	Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients[J]. N Engl J Med, 2017, 376(16): 1527-1539. doi:10.1056/NEJMoa1701488 URL
[20]	Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med, 2018, 379(22): 2097-2107. doi:10.1056/NEJMoa1801174 URL
[21]	Nambi V, Agha A. Inclisiran: a game changer in a changing game?[J]. J Am Coll Cardiol, 2021, 77(9): 1194-1196.
[22]	Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis[J]. J Am Coll Cardiol, 2021, 77(9): 1182-1193. doi:10.1016/j.jacc.2020.12.058pmid:33663735
[23]	Crea F, Libby P. Acute coronary syndromes[J]. Circulation, 2017, 136(12): 1155-1166. doi:10.1161/CIRCULATIONAHA.117.029870 URL
[24]	Xu S, Ni H, Chen H, et al. The interaction between STAT3 and nAChRα1 interferes with nicotine-induced atherosclerosis via Akt/mTOR signaling cascade[J]. Aging (Albany NY), 2019, 11(19): 8120-8138.
[25]	Xu S, Chen H, Ni H, et al. Targeting HDAC6 attenuates nicotine-induced macrophage pyroptosis via NF-kB/NLRP3[J]. Atherosclerosis, 2021, 317: 1-9. doi:10.1016/j.atherosclerosis.2020.11.021 URL
[26]	Chatterjee M, Rath D, Schlotterbeck J, et al. Regulation of oxidized platelet lipidome: implications for coronary artery disease[J]. Eur Heart J, 2017, 38(25): 1993-2005. doi:10.1093/eurheartj/ehx146pmid:28431006
[27]	Ridker PM, Everett BM, Thuren T, et al. Antiinflamma-tory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med, 2017, 377(12): 1119-1131. doi:10.1056/NEJMoa1707914 URL
[28]	Hansson GK. Inflammation and atherosclerosis[J]. Circulation, 2017, 136(20): 1875-1877. doi:10.1161/CIRCULATIONAHA.117.030484pmid:28916641
[29]	Costopoulos C, Timmins LH, Huang Y, et al. Impact of combined plaque structural stress and wall shear stress on coronary plaque progression, regression, and changes in composition[J]. Eur Heart J, 2019, 40(18): 1411-1422. doi:10.1093/eurheartj/ehz132pmid:30907406
[30]	Patel R, Janoudi A, Vedre A, et al. Plaque rupture and thrombosis are reduced by lowering cholesterol levels and crystallization with ezetimibe and are correlated with fluorodeoxyglucose positron emission tomography[J]. Arterioscler Thromb Vasc Biol, 2011, 31(9): 2007-2014. doi:10.1161/ATVBAHA.111.226167 URL
[31]	Libby P, Pasterkamp G, Crea F, et al. Reassessing the mechanisms of acute coronary syndromes[J]. Circ Res, 2019, 124(1): 150-160. doi:10.1161/CIRCRESAHA.118.311098 URL
[32]	Jia H, Dai J, Hou J, et al. Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion (the EROSION study)[J]. Eur Heart J, 2017, 38(11): 792-800.
[33]	Gao B, Zhang Z, Qian J, et al. The use of calcium channel blockers in the treatment of coronary spasm and atrioventricular block[J]. Cell Biochem Biophys, 2015, 72(2): 527-531. doi:10.1007/s12013-014-0498-zpmid:25572060
[34]	Gupta RM, Hadaya J, Trehan A, et al. A genetic variant associated with five vascular diseases is a distal regulator of endothelin-1 gene expression[J]. Cell, 2017, 170(3): 522-533. doi:10.1016/j.cell.2017.06.049 URL
[35]	Ford TJ, Corcoran D, Padmanabhan S, et al. Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction[J]. Eur Heart J, 2020, 41(34): 3239-3252. doi:10.1093/eurheartj/ehz915 URL
[36]	Bairey Merz CN, Pepine CJ, Shimokawa H, et al. Treatment of coronary microvascular dysfunction[J]. Cardiovasc Res, 2020, 116(4): 856-870. doi:10.1093/cvr/cvaa006pmid:32087007
[37]	Taqueti VR, Di Carli VMFR. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2018, 72(21): 2625-2641. doi:10.1016/j.jacc.2018.09.042 URL
[38]	Kaski JC, Crea F, Gersh BJ, et al. Reappraisal of ischemic heart disease[J]. Circulation, 2018, 138(14): 1463-1480. doi:10.1161/CIRCULATIONAHA.118.031373 URL
[39]	中国老年医学学会心血管病分会. 中国多学科微血管疾病诊断与治疗专家共识[J]. 中国循环杂志, 2020, 35(12): 1149-1165.
[40]	Suda A, Takahashi J, Hao K, et al. Coronary functional abnormalities in patients with angina and nonobstructive coronary artery disease[J]. J Am Coll Cardiol, 2019, 74(19): 2350-2360. doi:10.1016/j.jacc.2019.08.1056 URL
[41]	Tunc E, Eve AA, Madak-Erdogan Z. Coronary microvascular dysfunction and estrogen receptor signaling[J]. Trends Endocrinol Metab, 2020, 31(3): 228-238. doi:10.1016/j.tem.2019.11.001 URL

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献41

相关文章15

编辑推荐

Metrics

本文评价

[1]	许晴, 邵慧英, 陈帅, 全进伟, 周清芬, 王敏慧.延续健康教育和指导对干预2型糖尿病患者冠状动脉斑块进展的影响[J]. 内科理论与实践, 2022, 17(04): 330-333.
[2]	金姚, 黄晖, 吴志俊.分泌性白细胞蛋白酶抑制剂与急性冠脉综合征的关系[J]. 内科理论与实践, 2021, 16(04): 251-254.
[3]	陆浩, 葛雷.慢性完全闭塞病变介入治疗临床研究进展[J]. 内科理论与实践, 2021, 16(03): 145-150.
[4]	刘晓丽, 马晓腾.CYP2C19基因型与冠心病精准抗血小板治疗[J]. 内科理论与实践, 2021, 16(03): 161-166.
[5]	邵建伟, 胡赟赟, 倪通天, 陈敏, 周伟君, 毛恩强, 陈尔真.急性脑梗死患者神经功能缺损与颈动脉粥样硬化斑块关系的临床研究[J]. 内科理论与实践, 2021, 16(01): 32-36.
[6]	查晴, 于晨溪, 刘亚, 杨玲, 叶佳雯, 刘艳.miR-16在冠状动脉粥样硬化斑块进展中的作用及初步机制研究[J]. 诊断学理论与实践, 2021, 20(01): 82-87.
[7]	曹烨, 刘晓晟, 葛晓乾, 周斌.运用动态增强磁共振成像评估颈动脉粥样斑块稳定性的初步研究[J]. 诊断学理论与实践, 2019, 18(04): 436-441.
[8]	张颖, 樊子旭, 刘华, 马建伟, 张敏,.可溶性生长刺激表达基因2蛋白与冠状动脉粥样硬化病变的相关性[J]. 内科理论与实践, 2019, 14(02): 83-89.
[9]	李琳, 牛静雅, 王天歌, 李勉, 赵志云, 徐瑜, 陆洁莉, 徐敏, 毕宇芳, 王卫庆, 高金丽.上海市淞南社区中老年人群冠状动脉粥样硬化患病率CCTA调查结果及相关因素分析[J]. 诊断学理论与实践, 2018, 17(01): 38-44.
[10]	吴丽苹, 曹久妹.长链非编码RNA在冠状动脉粥样硬化性心脏病中的研究进展[J]. 诊断学理论与实践, 2017, 16(06): 664-667.
[11]	李俊伟, 夏寒冰, 赵红丽, 刘淑霞.基于超声测量的心外膜脂肪组织厚度预测冠心病的价值[J]. 诊断学理论与实践, 2017, 16(03): 324-327.
[12]	凌媛, 王书鸿, 梁伟, 沈琳辉.血清补体C1q肿瘤坏死因子相关蛋白1水平与冠状动脉粥样硬化性心脏病相关性研究[J]. 诊断学理论与实践, 2017, 16(02): 199-203.
[13]	买买提依明, 热西旦, 陈波, 张祥, 马卫英, 杨康, 傅毅.染色体9p21多态性与急性非心源性脑梗死患者颈动脉斑块的易感性分析[J]. 诊断学理论与实践, 2016, 15(05): 498-502.
[14]	陆寒英, 王泰蓉, 滕斌.2型糖尿病患者强化治疗过程中动脉脉搏波传导速度、踝臂指数及颈动脉斑块变化及分析[J]. 诊断学理论与实践, 2016, 15(05): 507-512.
[15]	杨汪洋, 马长生,.人类免疫缺陷病毒感染及抗病毒药物与冠心病关系的研究现状[J]. 内科理论与实践, 2016, 11(01): 52-56.